Biosimilar infliximab regulatory update

The European Commission approved an MAA from Samsung Bioepis Co. Ltd. for Flixabi infliximab, a biosimilar of autoimmune drug Remicade

Read the full 209 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE